Year Founded
2010
Ownership
Private
Employees
~50
Therapeutic Areas
Oncology
Stage
Phase 1
Modalities
Small molecule

AROG Pharmaceuticals General Information

Arog Pharmaceuticals has conducted Phase I trials for crenolanib targeting PDGFRA and PDGFRB in pediatric high-grade gliomas and DIPG. The trials demonstrated tolerability but no significant efficacy signals. A separate Phase I/Ib trial in gastrointestinal cancers was terminated early due to sponsor withdrawal.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Dallas, Texas
USA

Drug Pipeline

crenolanib
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to AROG Pharmaceuticals's pipeline data

Book a demo

Key Partnerships

No partnerships listed

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

AROG Pharmaceuticals Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view AROG Pharmaceuticals's complete valuation and funding history, request access »